- Home
- MIR vs MRUS Comparison
MIR vs MRUS Comparison
Compare MIR & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIR
- MRUS
- Stock Information
- Founded
- MIR 2005
- MRUS 2003
- Country
- MIR United States
- MRUS Netherlands
- Employees
- MIR N/A
- MRUS N/A
- Industry
- MIR Industrial Machinery/Components
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MIR Technology
- MRUS Health Care
- Exchange
- MIR Nasdaq
- MRUS Nasdaq
- Market Cap
- MIR 5.7B
- MRUS 5.1B
- IPO Year
- MIR N/A
- MRUS 2016
- Fundamental
- Price
- MIR $24.74
- MRUS $95.93
- Analyst Decision
- MIR Strong Buy
- MRUS Buy
- Analyst Count
- MIR 6
- MRUS 18
- Target Price
- MIR $28.50
- MRUS $93.72
- AVG Volume (30 Days)
- MIR 4.7M
- MRUS 1.3M
- Earning Date
- MIR 10-28-2025
- MRUS 10-31-2025
- Dividend Yield
- MIR N/A
- MRUS N/A
- EPS Growth
- MIR N/A
- MRUS N/A
- EPS
- MIR 0.10
- MRUS N/A
- Revenue
- MIR $902,300,000.00
- MRUS $56,606,000.00
- Revenue This Year
- MIR $8.20
- MRUS $52.81
- Revenue Next Year
- MIR $18.96
- MRUS N/A
- P/E Ratio
- MIR $234.47
- MRUS N/A
- Revenue Growth
- MIR 7.82
- MRUS 57.54
- 52 Week Low
- MIR $12.00
- MRUS $33.19
- 52 Week High
- MIR $30.28
- MRUS $96.28
- Technical
- Relative Strength Index (RSI)
- MIR 47.89
- MRUS 74.17
- Support Level
- MIR $22.48
- MRUS $95.63
- Resistance Level
- MIR $25.07
- MRUS $96.06
- Average True Range (ATR)
- MIR 1.49
- MRUS 0.37
- MACD
- MIR -0.45
- MRUS -0.46
- Stochastic Oscillator
- MIR 35.39
- MRUS 72.43
About MIR Mirion Technologies Inc.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.